Russian patient organizations ask Gilead to disclaim patents for Truvada

By |2020-09-03T16:30:29+03:0003.09.2020|Intellectual property, News|1 Comment

September 3, twenty-five patient organizations working in the field of HIV response in Russia published an open letter to Gilead Sciences, asking the pharmaceutical company to disclaim patent rights for the combination of tenofovir and emtricitabine, marketed under the tradename Truvada.